SAS Output

25-APR-2019 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1312-ALL, CD22+, REL/REF, Inotuzumab+CVP 1 Y 1 CVP + Inotuzumab dose level 1 38 5 0 0 0 0 0 06/13/2014    
        2 CVP + Inotuzumab dose level 2   5 0 0 0 0 0      
        3 CVP + Inotuzumab dose level 3   11 0 0 0 0 0      
        4 CVP + Inotuzumab dose level 4   5 0 0 0 0 0      
        5 CVP + Inotuzumab dose level 5   11 0 0 0 0 0      
        6 CVP + Inotuzumab MTD   13 12 5 2 1 0      
            50 12 5 2 1 0      
 
  S1318-ALL, Age 65+, Ph±, Blinatumomab 1 T 1 Induction: Ph- 44 31 0 0 0 0 0 06/30/2015 133 51
        2 Induction: Ph+/Ph-like   16 0 0 0 0 0      
            47 0 0 0 0 0      
 
    2 Y 3 Post-remission: Ph- 44 20 0 0 0 0 0 06/30/2015    
        4 Post-remission: Ph+/Ph-like   12 0 0 0 0 0      
            32 0 0 0 0 0      
 
    3 Y 5 Maintenance: Ph- 44 14 0 0 0 0 0 06/30/2015    
        6 Maintenance: Ph+/Ph-like   10 0 0 0 0 0      
            24 0 0 0 0 0      
 
  S1612-AML/MDS, Age 60+, Aza/Novel Therapeutics 1 T 0 FLT3 Testing 1670 113 96 0 0 0 0 02/02/2018 214 87
            113 96 0 0 0 0      
 
    2 T 1 Azacitidine 1670 26 19 0 0 0 0 02/02/2018    
        2 Azacitidine + Nivolumab   26 22 0 0 0 0      
        3 Azacitidine + Midostaurin   26 24 0 0 0 0      
            78 65 0 0 0 0      
 
  S1712-CML, Chronic Phase, TKI +/- Ruxolitinib 1 Y 1 Single Agent TKI 84 3 3 3 2 1 1 10/24/2018 159 60
        2 TKI + Ruxolitinib   3 3 2 2 0 0      
            6 6 5 4 1 1      
 
Yes E1910-BCR-ABL-neg, B ALL, Blinatumomab 1 E Total Registrations   111 31 10 9 2 0 06/06/2014 1 84
            111 31 10 9 2 0      
 
  E2906-AML, Age 60+, Clo vs Dauno+Cy 1 E Total Registrations   75 0 0 0 0 0 08/06/2012   40
            75 0 0 0 0 0      
 
  EA9161-CLL, untreated, IOV vs IO in younger pts 1 E Total Registrations   10 10 10 10 5 0 02/12/2019 130 55
            10 10 10 10 5 0      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   4 4 4 1 0 0 11/09/2018 160 56
            4 4 4 1 0 0      
 
    1 E Total Registrations   2 2 2 0 0 0 11/09/2018    
            2 2 2 0 0 0      
 
    2 E Total Registrations   1 1 1 0 0 0 11/09/2018    
            1 1 1 0 0 0      
 
  E1910-BCR-ABL-neg, B ALL, Blinatumomab 0 E Total Registrations   152 39 13 10 2 0 06/06/2014 1 84
            152 39 13 10 2 0      
 
    2 E Total Registrations   69 19 8 3 0 0 06/06/2014    
            69 19 8 3 0 0      
 
    3 E Total Registrations   58 17 11 6 1 0 06/06/2014    
            58 17 11 6 1 0      
 
    4 E Total Registrations   22 4 1 0 0 0 06/06/2014    
            22 4 1 0 0 0      
 
  E2906-AML, Age 60+, Clo vs Dauno+Cy 0 E Total Registrations   19 0 0 0 0 0 08/06/2012   40
            19 0 0 0 0 0      
 
    2 E Total Registrations   21 0 0 0 0 0 08/06/2012    
            21 0 0 0 0 0      
 
    3 E Total Registrations   11 0 0 0 0 0 08/06/2012    
            11 0 0 0 0 0      
 
  NHLBIMDS-LEUK, National MDS Study 1 E Total Registrations   37 27 18 13 6 1 12/22/2016 209 80
            37 27 18 13 6 1